Apellis Pharmaceuticals Inc (APLS)

$37.55

-1.39

(-3.56%)

Live

Insights on Apellis Pharmaceuticals Inc

  • Increasing Revenue

    Revenue is up for the last 6 quarters, 14.38M → 89.64M (in $), with an average increase of 27.8% per quarter

  • Increasing Net Profit

    Netprofit is up for the last 2 quarters, -177.77M → -122.03M (in $), with an average increase of 45.7% per quarter

  • Vs NVO

    In the last 1 year, Novo Nordisk A/s has given 66.6% return, outperforming this stock by 102.2%

  • Vs NVO

    In the last 3 years, Novo Nordisk A/s has given 155.7% return, outperforming this stock by 129.2%

Performance

  • $36.97
    $38.57
    $37.55
    downward going graph

    1.56%

    Downside

    Day's Volatility :4.16%

    Upside

    2.64%

    downward going graph
  • $19.83
    $94.75
    $37.55
    downward going graph

    47.19%

    Downside

    52 Weeks Volatility :79.07%

    Upside

    60.37%

    downward going graph

Returns

PeriodApellis Pharmaceuticals IncSector (Health Care)Index (Russel 2000)
3 Months
-55.89%
-3.2%
0.0%
6 Months
-50.11%
-2.7%
0.0%
1 Year
-35.63%
0.8%
-0.4%
3 Years
17.95%
22.3%
14.9%

Highlights

Market Capitalization
4.5B
Book Value
$2.94
Dividend Share
0.0
Dividend Yield
0.0%
Earnings Per Share (EPS)
-5.59
Wall Street Target Price
67.64
Profit Margin
0.0%
Operating Margin TTM
-331.93%
Return On Assets TTM
-39.92%
Return On Equity TTM
-193.31%
Revenue TTM
184.5M
Revenue Per Share TTM
1.63
Quarterly Revenue Growth YOY
481.79999999999995%
Gross Profit TTM
69.8M
EBITDA
-610.9M
Diluted Eps TTM
-5.59
Quarterly Earnings Growth YOY
0.0
EPS Estimate Current Year
-4.73
EPS Estimate Next Year
-2.59
EPS Estimate Current Quarter
-1.32
EPS Estimate Next Quarter
-1.3

Analyst Recommendation

Buy
    80%Buy
    19%Hold
    0
    0%Sell
Based on 21 Wall street analysts offering stock ratings for Apellis Pharmaceuticals Inc(by analysts ranked 0 to 5 stars)
Based on 21 analyst
  • Current
  • 1M Ago
  • 3M Ago
Buy
17
18
18
Hold
4
5
5
Sell
00
00
00

Analyst Forecast

What analysts predicted

Upside of 80.13%

Current $37.55
Target $67.64

Technicals Summary

Sell

Neutral

Buy

Apellis Pharmaceuticals Inc is currently in a neutral trading position according to technical analysis indicators.

Peers

Company Name1 Month6 Month1 Year3 Years5 Years
Apellis Pharmaceuticals Inc
Apellis Pharmaceuticals Inc
-9.66%
-50.11%
-35.63%
17.95%
138.87%
Moderna, Inc.
Moderna, Inc.
-5.74%
-34.14%
-17.98%
43.27%
454.19%
Regeneron Pharmaceuticals, Inc.
Regeneron Pharmaceuticals, Inc.
-1.77%
-1.68%
9.3%
33.59%
106.18%
Novo Nordisk A/s
Novo Nordisk A/s
-7.65%
10.71%
66.6%
150.37%
305.83%
Seagen, Inc.
Seagen, Inc.
2.57%
3.72%
52.7%
4.95%
167.21%
Vertex Pharmaceuticals Incorporated
Vertex Pharmaceuticals Incorporated
-0.89%
9.77%
14.81%
28.32%
82.99%
Company NameP/E RatioP/B RatioPEG RatioEPSROEROADiv YieldBVPS
Apellis Pharmaceuticals Inc
Apellis Pharmaceuticals Inc
NA
NA
NA
-4.73
-1.93
-0.4
0.0
2.94
Moderna, Inc.
Moderna, Inc.
34.44
34.44
0.0
-3.45
0.07
0.01
0.0
44.49
Regeneron Pharmaceuticals, Inc.
Regeneron Pharmaceuticals, Inc.
21.94
21.94
9.01
41.82
0.19
0.1
0.0
225.94
Novo Nordisk A/s
Novo Nordisk A/s
43.71
43.71
2.03
1.66
0.82
0.22
0.01
2.52
Seagen, Inc.
Seagen, Inc.
NA
NA
18.53
-3.52
-0.26
-0.13
0.0
13.96
Vertex Pharmaceuticals Incorporated
Vertex Pharmaceuticals Incorporated
27.05
27.05
0.41
14.71
0.25
0.16
0.0
60.01
Company NameAnalyst ViewMarket Cap5 Years Return %PE RatioProfit Margin
Apellis Pharmaceuticals Inc
Apellis Pharmaceuticals Inc
Buy
$4.5B
138.87%
NA
0.0%
Moderna, Inc.
Moderna, Inc.
Buy
$39.3B
454.19%
34.44
11.33%
Regeneron Pharmaceuticals, Inc.
Regeneron Pharmaceuticals, Inc.
Buy
$88.8B
106.18%
21.94
33.93%
Novo Nordisk A/s
Novo Nordisk A/s
Buy
$411.7B
305.83%
43.71
33.4%
Seagen, Inc.
Seagen, Inc.
Hold
$39.7B
167.21%
NA
-33.55%
Vertex Pharmaceuticals Incorporated
Vertex Pharmaceuticals Incorporated
Buy
$89.1B
82.99%
27.05
35.4%

Institutional Holdings

  • venBio Select Advisor LLC

    9.44%
  • Vanguard Group Inc

    7.99%
  • T. Rowe Price Associates, Inc.

    6.01%
  • Wellington Management Company LLP

    5.66%
  • BlackRock Inc

    4.88%
  • T. Rowe Price Investment Management,Inc.

    4.79%

Corporate Announcements

  • Apellis Pharmaceuticals Inc Earnings

    Apellis Pharmaceuticals Inc’s price-to-earnings ratio stands at None

    Read More

Company Information

apellis pharmaceuticals is an early stage biotechnology company applying immunotherapy to auto-immune diseases, with an initial emphasis on diseases of the lungs such as asthma and chronic obstructive pulmonary disease (copd), diseases of the retina such as age-related macular degeneration (amd), and rare hematological diseases such as paroxysmal nocturnal hemoglobinuria (pnh). apellis believes that targeting a key element in the immune system called the complement system can have profound disease modifying benefits. we call this approach complement immunotherapy.

Organization
Apellis Pharmaceuticals Inc
Employees
767
CEO
Dr. Cedric Francois M.D., Ph.D.
Industry
Distribution Services

FAQs